Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEB-01 in Pancreatic Cancer
NCT06538857Phase 1Active, not recruiting
- Sponsor
- Cebiotex
- Start
- Aug 2024
- Primary completion
- Sep 2028
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of CEB-01 in pancreatic cancer (PC) (2 arms), sponsored by Cebiotex. Primary endpoints: Frequency of Adverse Events at 3 years and Frequency of surgical complications after pancreatic surgery at 3 years. Started Aug 2024; status: active, not recruiting.
02
Drugs
CEB-01
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06538857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06538857.